SCIP RHD: Are SubCutaneous Infusions of benzathine Penicillin G (BPG) longer lasting and more acceptable than intramuscular BPG in children with Rheumatic Heart Disease?

Phase 2

Recruiting

• Conditions: rheumatic fever; rheumatic heart disease; Cardiovascular - Other cardiovascular diseases; Infection - Other infectious diseases

• Registration Number: ACTRN12622000916741
• Lead Sponsor: niversity of Otago

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-06-27
• Last Update Posted: 18 March 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 65

Inclusion Criteria

Aged 6 years of age or older with a prior diagnosis of rheumatic fever or rheumatic heart disease.
Currently on secondary prophylaxis.
No prior documented allergy to penicillin, cephalosporin antibiotics.
Normally reside in New Zealand.

Exclusion Criteria

History of adverse drug reaction or hypersensitivity.
Planned absence from their usual place of residence during the study trial.
History within the last 12 months of intramuscular, or subcutaneous injection of the abdominal wall, or history of surgery to the buttocks, abdomen or abdominal wall within the last 12 months.
Pregnancy.
Scarring or superficial changes on the abdomen.
Dermatological conditions that affect the abdomen

Study & Design

• Study Type: Interventional
• Study Design: Not specified